Singapore markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
38.06-0.11 (-0.29%)
At close: 4:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close38.17
Open38.01
Bid38.04 x 3100
Ask38.10 x 1400
Day's range37.93 - 38.39
52-week range27.88 - 40.97
Volume11,878,033
Avg. volume31,021,196
Market cap211.495B
Beta (5Y monthly)0.73
PE ratio (TTM)15.07
EPS (TTM)2.53
Earnings date27 Oct 2020 - 02 Nov 2020
Forward dividend & yield1.52 (3.98%)
Ex-dividend date30 Jul 2020
1y target est41.85
  • What's the Outlook for BioNTech Stock?
    Motley Fool

    What's the Outlook for BioNTech Stock?

    As of today, 167 COVID-19 vaccine candidates are in development around the world with 28 in clinical human trials. In response, demand for coronavirus vaccine stocks has soared as investors try to pick the most likely winners of the vaccine race. One of the most promising vaccine candidates is being jointly developed by two large-cap biotech companies, BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE).

  • Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?
    Motley Fool

    Could Inovio Pharmaceuticals Be a Millionaire-Maker Stock?

    Buy shares of a company that isn't profitable yet and doesn't even have consistent revenue. Inovio Pharmaceuticals (NASDAQ: INO) definitely fits the bill of a company that isn't generating a profit right now and doesn't have products on the market to generate a reliable revenue stream. Could Inovio be a millionaire-maker stock?

  • Moderna and Other Coronavirus Vaccine Makers to Take Reduced Payments If Approval Milestones Not Met
    Motley Fool

    Moderna and Other Coronavirus Vaccine Makers to Take Reduced Payments If Approval Milestones Not Met

    If Moderna (NASDAQ: MRNA) and its peers take too long to get their current coronavirus vaccine candidates fully developed and approved, they could pay the price. The government is mandating that they meet ambitious targets for this. Moderna, for example, will receive $1.5 billion from the government if its MRNA-1273 candidate is approved for use by Jan. 31, 2021.